President Trump’s repeated assertions the United States is “rounding the turn” on the novel coronavirus have increasingly alarmed the government’s top health experts, who say the country is heading into a long and potentially deadly winter with an unprepared government unwilling to make tough choices.
“We’re in for a whole lot of hurt. It’s not a good situation,” Anthony S. Fauci, the country’s leading infectious-disease expert, said in a wide-ranging interview late Friday. “All the stars are aligned in the wrong place as you go into the fall and winter season, with people congregating at home indoors. You could not possibly be positioned more poorly.”
Fauci, a leading member of the government’s coronavirus response, said the United States needed to make an “abrupt change” in public health practices and behaviors. He said the country could surpass 100,000 new coronavirus cases a day and predicted rising deaths in the coming weeks. He spoke as the nation set a new daily record Friday with more than 98,000 cases. As hospitalizations increase, deaths are also ticking up, with more than 1,000 reported Wednesday and Thursday, bringing the total to more than 229,000 since the start of the pandemic, according to health data analyzed by The Washington Post.
Fauci’s blunt warnings come as Trump has rallied in states and cities experiencing record surges in infections and hospitalizations in a last-ditch effort to convince voters he has successfully managed the pandemic. He has held maskless rallies with thousands of supporters, often in violation of local health mandates.
Even as new infections climb in 42 states, Trump has downplayed the virus or mocked those who take it seriously. “Covid-19, covid, covid, covid,” he said during one event, lamenting that the news media gives it too much attention. In another rally, he baselessly said that U.S. doctors record more deaths from covid-19, the disease the coronavirus causes, than other nations because they get more money.
“I mean our doctors are very smart people. So what they do is they say, ‘I’m sorry but everybody dies of covid,’ ” Trump said Friday at a rally in Waterford Township, Mich., without offering any evidence.
Fauci said former vice president Joe Biden’s campaign “is taking it seriously from a public health perspective.” Trump, Fauci said, is “looking at it from a different perspective.” He said that perspective was “the economy and reopening the country.”
[Tracking coronavirus cases across the U.S.]
Fauci, who once took a starring role in the response and briefed the president almost every day as director of the National Institute of Allergy and Infectious Diseases, described a disjointed response as cases surge. Several current and former senior administration officials said the White House is almost entirely focused on a vaccine, even though experts warn it is unlikely to be a silver bullet that ends the pandemic immediately since it will take months under the best of circumstances to inoculate tens of millions
Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies
MELBOURNE, Australia, Oct. 25, 2020 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Cogstate, Ltd. (Headquarters: Melbourne, Australia and New Haven, USA, CEO: Brad O’Connor, “Cogstate”) announced today that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the “Cogstate Brief BatteryTM” (CBB) for use in healthcare and other markets. This global licensing deal is an expansion of an existing partnership executed in August 2019 whereby Eisai secured exclusive development and commercialization rights in Japan for all cognitive function tests developed by Cogstate, including the CBB. Both companies plan to proceed with development globally of CBB as a tool for individuals to self-assess brain performance to support healthy lifestyle choices and preventative measures in daily life, as well as a medical device to aid healthcare professionals in clinical diagnosis decisions.
Developed by Cogstate, the CBB is a scientifically validated digital tool that enables cognitive function self-checks and consists of four tests evaluating psychomotor function, attention, learning and memory, and working memory. In the United States, Europe, Australia, New Zealand and Canada, the CBB has been adapted as a medical device named “CognigramTM” that has achieved marketing authorization by regulators in these jurisdictions and provides informative results for healthcare professionals to support clinical examination to aid in the diagnosis of MCI and dementia.
In its medium-term business plan, EWAY2025, Eisai is aiming to become a “Medico Societal Innovator” (a company that changes society through creating medicines and providing solutions). Eisai is creating next-generation medical remedies focused on the neurology and oncology areas as well as building disease ecosystem platforms, in order to provide environments and solutions including digital solutions for early diagnosis and early treatment.
Cogstate aims to make assessment of brain health as simple, common and informative as assessment of blood pressure. Cogstate’s technology, which is easy to use and available in over 70 languages, is supported by extensive scientific validation, including more than 600 peer reviewed publications. Cogstate technology has been used extensively in clinical trials, including trials conducted by Eisai.
The global agreement between Eisai and Cogstate will allow the two companies to replicate many of the advancements that have already been launched in Japan, where Eisai has developed and launched a new digital tool using the CBB, named “NouKNOWTM” (pronounced “NOH-NOH”), a non-medical device for self-assessment of brain performance (brain health). Eisai is currently investigating the possibility of developing a medical device using the CBB in Japan.
In recent years, various research has demonstrated the possibility that decline in brain performance may be mitigated through major readjustments to lifestyle, such as regular exercise and sleep, a well-balanced diet, and social interaction. However, according to a survey by Eisai, the number of people taking correct preventive actions or habitually performing self-checks of cognitive function are few,